Tuberculosis (TB) affects mostly young people in their most productive years and the long treatment with its many side effects is a challenge for patients. A vaccine that protects better from developing TB or an immunotherapeutic intervention that shortens the lengthy treatment would be great assets in fighting the current (MDR-) TB epidemic. My PhD focuses on new vaccine interventions against tuberculosis and notably multidrug-resistant tuberculosis. The laboratory part of my MD / PhD evolves around recombinant BCG vaccine strains and their immunological characterisation in vitro and in vivo.
Click to view graph
Click to view timeline
I am a MD / PhD student at the University of Groningen, The Netherlands. During my Masters internship I joined the lab of Roland Brosch and returned for a second visit as PhD student.
2017Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection, Cell Reports 2017, 18, (11), 2752–2765.
2016ESX secretion systems: mycobacterial evolution to counter host immunity, Nat. Rev. Microbiol. 2016, 14(11):677-691..
2016CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection, PLoS Pathog. 2016 Jul 28;12(7):e1005770. doi: 10.1371/journal.ppat.1005770..
2016Type VII Secretion Systems in Gram-Positive Bacteria, Curr. Top. Microbiol. Immunol. 2016 Jan;.
2015Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo, PLoS Pathog. 2015 Feb;11(2):e1004650.